Brand name authorized in: Netherlands
The drug AAFACT contains one active pharmaceutical ingredient (API):
Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X (factor Xa). Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
This drug has been assigned below unique identifiers within the countries it is being marketed: